Resources
Did you mean
prescription drug (25 results), drug company (17 results), drug testing (14 results), drugstore (6 results)
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- GSK to Pay Actelion Up to $3.3 Bln For Drug Rights
- By Sam Cage and Sven Egenter ZURICH (Reuters) - GlaxoSmithKline Ltd GSK could pay Swiss company Actelion Ltd ATLN up to 3.3 billion Swiss francs ($3.28 billion) to develop a promising insomnia drug in the largest biotech partnering deal. Glaxo, Europe's biggest drugmaker,...
- News items 2008-07-14
- GSK to Pay Actelion Up to 1.6 Bln For Drug Rights
- By Sam Cage and Sven Egenter ZURICH (Reuters UK) - GlaxoSmithKline GSK could pay Swiss company Actelion ATLN up to 3.3 billion Swiss francs (1.6 billion pounds) to develop a promising insomnia drug in the largest biotech partnering deal. Glaxo, Europe's biggest drugmaker, beat many of...
- News items 2008-07-14
- Top Drug Companies' Earnings Beat Forecasts
- By Ben Hirschler LONDON (Reuters UK) - The world's two biggest drugmakers, Pfizer PFE and GlaxoSmithKline GSK, both beat expectations for quarterly earnings on Wednesday, as did Wyeth WYE, indicating the sector's resilience. Although all three companies face major threats from generic competition, the latest...
- News items 2008-07-23
- Top Drug Companies' Earnings Beat Forecasts
- By Ben Hirschler LONDON (Reuters) - The world's two biggest drugmakers, Pfizer Inc PFE and GlaxoSmithKline Plc GSK, both beat expectations for quarterly earnings on Wednesday, as did Wyeth WYE, indicating the sector's resilience. Although all three companies face major threats from ...
- News items 2008-07-23
- Bribing Pharma to Focus on Health Disasters
- For all its rhetoric about advancing human health, the drug industry has never shown much interest in tropical diseases that kill or plague millions of people, for the very simple reason that poor nations can't pay top dollar for new drugs. That may be changing, though, thanks to a new...
- Blog posts 2008-07-17
- Doctors vs. Drug Companies: Pharma is Winning -- So Far
- Earlier this week, the WSJ noted that oncologists are getting squeezed on the cost of expensive cancer drugs. Although the story features the usual anecdotes of doctors whose practices are in debt or who are shunting patients off to hospitals for treatment in order to save money, it's still hard...
- Blog posts 2008-07-10
- Glaxo Wellcome: Fighting Disease and Improving Health
- Intent on improving its ability to bring new drugs to market, global pharmaceutical company Glaxo Wellcome embarked on a comprehensive redesign of its clinical development processes. Glaxo Wellcome aims to be the leading global company in fighting disease and improving health. Its R&D organization spends in the region of $2...
- Case studies
- HTG
- High Throughput Genomics, Inc., HTG, is a provider of transcriptomic technology and services. HTG's technology opens a new era of drug discovery and allows companies to identify new drug compounds, quickly eliminate less promising compounds and bring new drugs to market faster. Researchers and scientists are often jaded by biotech...
- Case studies
- FDA to Biotech: Don't Blame Us For Your Cruddy Data
- For the past few years, a coterie of biotech executives, desperate patients and ideologues have waged a low-level but steady campaign to convince the country that the Food and Drug Administration is condemning sick Americans to death by denying them potentially life-saving cancer drugs and other treatments. For all three,...
- Blog posts 2008-05-29
- Performance-Enhancing Drugs at Work: An Ethics Poll
- Is the asterisk coming to the business world? The use of performance-enhancing drugs has clogged up the sports world for the last couple of years, but steroid and human growth hormone are not the only way to get a chemical advantage. What about the brain drugs, those...
- Blog posts 2008-05-12
- The Week That Was in Pharma
- Welcome back from the weekend. Here's a quick roundup of stories you may have overlooked over the past week: Merck said it would cut 1,200 jobs following the FDA's rejection of one cholesterol drug and a scandal that's cuts sales of its combination drug Vytorin, which it...
- Blog posts 2008-05-12
- FDA Loosens Rules for Overseas Drug Trials
- Merrill Goozner, a former Chicago Tribune reporter turned public-health advocate he heads up the Integrity in Science Project at the Center for Science in the Public Interest, notes an interesting and almost wholly overlooked Food and Drug Administration decision that may have the effect of subjecting clinical-trial volunteers in poor...
- Blog posts 2008-05-08
- Man Bites Dog: Former Merck CEO Blasts High Drug Prices
- Most pharmaceutical companies insist that high drug prices are a natural consequence of the risky business of drug discovery, and that huge profits on marketed drugs are necessary to cover the costs of the 5,000 to 10,000 experimental drugs that fail for every one that succeeds. In fact, there are...
- Blog posts 2008-05-05
- Life Without Blockbusters: What Valeant's Woes Portend for Pharma
- It's now a truism that the drug industry's "blockbuster model" has pretty much had its day. Much of Big Pharma is having a terrible time winning approval for new drugs and even keeping up sales of existing blockbusters, in part because their underlying rationale -- that pushing drugs into mass...
- Blog posts 2008-05-05
- Glaxo Makes Like Ponce de Leon With Sirtris Buy
- You can't fault GlaxoSmithKline for temerity. The U.K. drugmaker's unexpectedly large $720 million bid for Sirtris Pharmaceuticals represents a gutsy bet that the Massachusetts biotech really has a handle on a class of drugs that slow aging. Not that anyone at either company is eager to describe their work that...
- Blog posts 2008-04-22
- New Lows in Health Insurance -- Pay More for Drugs, If You Can Afford Them
- The basic social bargain of health insurance -- that we all pay premiums while we're healthy so insurance will cover our costs when we're sick -- has been breaking down for close to two decades. To see how high drug prices are shredding it further, look no further than today's...
- Blog posts 2008-04-14
- Pfizer Leads in Layoffs While Drug Prices Soar
- Big Pharma continues to lend new meaning to the phrase "doing more with less," because while the industry seems to get smaller every day, drugmakers are still pushing through big price increases on their leading products. Over at Pharmalot, Ed Silverman provides a helpful roundup tracking the...
- Blog posts 2008-04-10
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
- Brain Steroids: Ban Or Boost?
- Drugs are bad for productivity, right? Well, maybe not. While you can probably correlate productivity increases with declines in per capita drinking, what about coffee or Diet Coke? These can act as mild stimulants. Then there's full-fledged brain steroids, say, a drug like Provigil, which...
- Blog posts 2008-03-24
- << Previous
- page 1 of 2
- Next >>
Content Types
Refining Tags
- David P. Hamilton (12 results)
- Pharmaceutical Company (9 results)
- Human Resources (7 results)
- Government (6 results)
- Federal Government (6 results)
- Management (5 results)
- Business Operations (5 results)
- Pfizer Inc. (5 results)
- Drug Company (5 results)
- Healthcare (5 results)
- Health Care (5 results)
- Benefits (5 results)
- GlaxoSmithKline Plc. (4 results)
- Marketing (4 results)
- Strategy (4 results)
- FDA (4 results)
- Enterprise Software (4 results)
- Software (4 results)
- Biotechnology (3 results)
- Marketing Research (3 results)
- Vertical Industries (3 results)
- Finance (3 results)
- Patient (3 results)
- Merck & Co. Inc. (3 results)
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
